Zydus Cadila receives final approval for Pioglitazone HC1 tablets

14 Feb 2013 Evaluate

Zydus Cadila, an innovative global pharmaceutical company, has received the final approval from US Food Drug and Administrator (USFDA) to market Pioglitazone HC1 tablets in different strengths of 15mg, 30mg and 45mg. The drug falls in the anti-diabetics segment.

The estimated sales in 2012 as per IMS for Pioglitazone HC1 tablets was $2 billion. Further, the group now has 75 approvals and has so far filed 170 ANDAs since the commencement of filing process in FY 2003-04.

Flagship company of Zydus Cadila Group, it focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

1001.15 -22.45 (-2.19%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.